AARTIDRUGS
Aarti Drugs Limited Q1 FY27: Revenue Up 19%, Ebitda Margin Expands 120 Bps
Aarti Drugs Limited (NSE: AARTIDRUGS) reports Q1 FY27 revenue up 19% YoY, EBITDA margin expands 120 bps, driven by growth in API & Specialty Chemicals.
Aarti Drugs Limited (Aarti Drugs) (NSE: AARTIDRUGS), a diversified pharmaceutical company, announced its unaudited financial results for Q1 FY27, ended 30th June 2026. The company reported a revenue of Rs. 703.6 crore, up 19% year-on-year (YoY) compared to Rs. 590.8 crore in Q1 FY26. The earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at Rs. 96.9 crore, a 30% YoY increase from Rs. 74.4 crore in Q1 FY26. EBITDA margin expanded by 120 basis points to 13.8% from 12.6% in the same quarter last year.
Segmental Performance
The Active Pharmaceutical Ingredients (API) segment recorded a revenue of Rs. 510.4 crore, up 11% YoY. The formulation segment saw a 7% YoY growth, contributing Rs. 86.2 crore. Specialty Chemicals revenue surged 150% YoY to Rs. 82.6 crore. Intermediates & Others reported a 26% YoY growth to Rs. 24.3 crore.
Standalone Business Highlights
The standalone business revenue stood at Rs. 627.6 crore, up 20% YoY. The domestic market contributed 68% to the revenue, while exports accounted for 32%. The anti-biotic therapeutic category in the API business contributed 35% to total API sales, followed by anti-protozoal (18.5%), anti-inflammatory (11.9%), anti-diabetic (18.2%), and antifungal (10.2%).
Commenting on the results, Mr. Adhish Patil, CFO & COO, Aarti Drugs Limited, said, “We began FY27 with a strong operational and financial performance, driven by a mix of volume growth and improved realizations across our API & Specialty Chemicals portfolio and disciplined execution. The quarter marked a recovery in the pricing environment compared to the previous year, while our continued focus on operational efficiencies and product mix supported profitability. Despite an uncertain and volatile global environment, Aarti Drugs delivered a robust quarter as production across our facilities continued without disruption, reflecting the resilience of our business model.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Aarti Drugs Limited
Aarti Drugs Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Aarti rises 12.3% over three months, with buying pressure holding steady. The PEG reaches 3.65, hard to justify given the growth. The market prices in a turnaround that has not arrived. Thin margins at 7.6% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock holds at 48% of its 52-week range with RSI at 64. In other words, neither side has a clear edge right now. Price climbs recently despite -1.8% revenue growth and a PEG of 3.65. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Aarti Drugs Limited.
AARTIDRUGS
Aarti Drugs Limited (AARTIDRUGS) breaks out, gains 5% intraday
Aarti Drugs Limited (NSE: AARTIDRUGS) stock breaks out, moving up 5% intraday to ₹444.0, clearing its 6M resistance trendline.
Aarti Drugs Limited (AARTIDRUGS) breaks out with a +5% gain to ₹444.0, clearing its 6M resistance trendline. This move follows the company’s announcement regarding pending litigation, which may have alleviated some investor concerns. In the healthcare sector, Aarti Drugs specializes in drug manufacturing, and today’s breakout suggests a company-specific catalyst rather than broad sector momentum.
Technical setup — trendlines & DMA
From a technical standpoint, Aarti Drugs has established a new support floor at ₹421.46, with today’s price sitting comfortably above it by 5.08%. The recent breakout above the 6M resistance at ₹432.94 indicates a shift in momentum. The 50-DMA at ₹391.6 and 200-DMA at ₹388.8 are both below the current price, suggesting the stock is not merely recovering but showing sustained upward pressure. Currently trading in the middle third of its 52W range, the stock has room to run, implying that not all of the potential upside is yet priced in.
Snapshot: ₹444.00 on 2026-08-11 (chart frozen at publication)
Fundamentals & business context
Despite a PE of 20.2, Aarti Drugs’ profit margin of 7.1% and a declining revenue CAGR of -1.8% raise questions about the valuation. The market seems to be pricing in a turnaround, but the current earnings don’t fully justify the premium. Institutional ownership stands at 11.0%, indicating a cautious but present interest from smart money. There was no specific NSE catalyst today, making the breakout even more intriguing from a fundamental perspective.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally weak position for Aarti Drugs. Two of the strongest signals are the breakout above resistance levels with momentum and the bullish sentiment over the last 30 days, where up days have seen 1.29x the volume of down days. These indicators suggest systematic accumulation and positive market sentiment. On the flip side, the company’s low profit margin of 7.1% and overvalued PEG ratio of 3.65 are significant risks. Thin margins leave little room for error, while the high PEG suggests the stock may be expensive relative to its growth rate.
Company outlook
Management provided an optimistic outlook for Aarti Drugs, expecting volume growth to surpass the June quarter as prices stabilize. They anticipate 10% to 15% volume growth over the next two years, driven by existing capacities and new projects. The EBITDA margin target is set above 14%, with the potential to reach 15% as utilization of greenfield projects improves. The Sayakha facility is expected to significantly contribute to gross margins once utilization exceeds 65%. Additionally, the company plans to scale up Metformin capacity to around 2,200 tons per month and construct new USFDA capacity, expected to be completed in 10 to 12 months.
Get all details on AARTIDRUGS — P&L, peers, shareholding and more on TradeAlone.
AARTIDRUGS
Aarti Drugs Limited (AARTIDRUGS) sees profit-taking after breakout, falls 5%
Aarti Drugs Limited (NSE: AARTIDRUGS) shows pressure after breakout, falling 5% intraday to ₹404.5. This retracement follows clearing 6M resistance.
Aarti Drugs Limited (AARTIDRUGS) pulls back after breakout, falling -5% intraday to ₹404.5 on the NSE on 22 Jul 2026. The stock has cleared its 6-month resistance at ₹395.17 but is retracing today as profit-taking sets in. This move is purely technical, with no fresh news or filings driving it. Aarti Drugs, a specialty and generic drug manufacturer, operates in a sector that has seen mixed momentum. Today’s pullback appears to be company-specific rather than a sector-wide trend.
Technical setup — trendlines & DMA
From a chart perspective, Aarti Drugs is currently trading above its 6-month support trendline at ₹366.85, which is 9.31% below today’s price. The stock has broken above the 6-month resistance trendline at ₹395.17, marking a breakout. However, it is currently 12% above the 50-DMA at ₹381.7, indicating an extended move. The 200-DMA stands at ₹395.7, slightly below the current price. The stock is in the middle third of its 52-week range, suggesting that a significant portion of the recent upward move may already be priced in.
Snapshot: ₹404.50 on 2026-07-22 (chart frozen at publication)
Fundamentals & business context
On the fundamental side, Aarti Drugs trades at a PE of 20.0, which appears stretched given its profit margin of 7.6% and a revenue CAGR of -1.8% over the past 5 years. The market seems to be pricing in potential turnaround or future growth, despite the current revenue decline. Institutional ownership stands at 11.1%, indicating a moderate level of confidence from smart money. There has been no NSE filing or catalyst in the last two days to explain today’s move.
Algorithmic scorecard
The algorithmic scorecard paints a picture of a stock that is technically strong but fundamentally weak. The technical strength is driven by the recent breakout above resistance and strong bullish sentiment over the past 30 days, where up days have seen 1.49x the volume of down days. However, the fundamental weaknesses are notable, particularly the declining revenue CAGR and thin profit margins. The stock’s PEG ratio of 3.70 suggests it is overvalued relative to its growth rate, and the negligible dividend yield offers little income for investors. These fundamental risks could pose challenges if the technical momentum wanes.
Company outlook
In their Q4FY26 concall, Aarti Drugs management outlined several key initiatives and targets. They aim for EBITDA margins between 13.5% to 14% for FY 2027. The company expects price growth in antibiotics, though volumes may remain flattish. Profitability is expected to improve gradually as utilization rates increase across newly commissioned facilities. Specifically, they plan to achieve around 55% to 60% utilization for the methylamine plant in the June quarter, rising to 70% within a year. Capex plans include INR 300 crores to INR 400 crores over the next two to three years for brownfield and quasi-greenfield projects, with a focus on developing oncology products.
Get all details on AARTIDRUGS — P&L, peers, shareholding and more on TradeAlone.
-
COFORGE2 days agoCoforge Limited (NSE: Coforge) Wins ‘AI Native Enterprise’ Award at TOI AI Quotient Awards
-
Communication Services2 days agoInfo Edge (india) Limited Announces Himanshu Agarwal as New CFO
-
EMUDHRA2 days agoEmudhra Limited (emudhra) Becomes Validation Agent for LEI Issuance in India
-
Auto Manufacturers2 days agoHyundai Motor India Limited Announces the Name of its Much-awaited Intelligent SUV
-
COFORGE2 days agoCoforge Limited (coforge) Expands Footprint with New Special Economic Zone Plots
-
Basic Materials2 days agoSolar Industries India Limited (solarinds) Expands Global Footprint with Acquisition of South Africa’s Omnia
-
Credit Services2 days agoSatin Creditcare Network Limited (satin): Satin Growth Alternatives Limited Invests in Indic Wisdom
-
CUMMINSIND18 hours agoCummins India Limited (cumminsind) Unveils Next-generation Power Solutions at Bauma Conexpo India 2026